Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0C4XQ
|
||||
Former ID |
DNC006404
|
||||
Drug Name |
GB-12819
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [528130] | ||
Structure |
Download2D MOL |
||||
Formula |
C29H33F2NO
|
||||
Canonical SMILES |
C1CN(CCC1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C<br />4)F
|
||||
InChI |
1S/C29H33F2NO/c30-27-13-9-25(10-14-27)29(26-11-15-28(31)16-12-26)33-22-21-32-19-17-24(18-20-32)8-4-7-23-5-2-1-3-6-23/h1-3,5-6,9-16,24,29H,4,7-8,17-22H2
|
||||
InChIKey |
VMIZSAUBUHOYHI-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Cytochrome P450 2D6 | Target Info | Inhibitor | [528130] | |
Sodium-dependent dopamine transporter | Target Info | Inhibitor | [526396] | ||
Pathway Interaction Database | Alpha-synuclein signaling | ||||
WikiPathways | Metapathway biotransformation | ||||
Tamoxifen metabolism | |||||
Oxidation by Cytochrome P450 | |||||
Vitamin D Receptor Pathway | |||||
Aripiprazole Metabolic Pathway | |||||
Fatty Acid Omega Oxidation | |||||
Codeine and Morphine MetabolismWP727:Monoamine Transport | |||||
NRF2 pathway | |||||
Dopaminergic Neurogenesis | |||||
Parkinsons Disease Pathway | |||||
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||||
Neurotransmitter Clearance In The Synaptic Cleft | |||||
References | |||||
Ref 526396 | Bioorg Med Chem Lett. 2002 Sep 2;12(17):2387-90.Synthesis and dopamine transporter binding affinities of 3alpha-benzyl-8-(diarylmethoxyethyl)-8-azabicyclo[3.2.1]octanes. | ||||
Ref 528130 | J Med Chem. 2006 Apr 20;49(8):2417-30.Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.